These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32063102)

  • 21. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
    Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism.
    Trujillo-Santos J; Beroiz P; Moustafa F; Alonso A; Morejon E; López-Reyes R; Casado I; Porras JA; Flores K; López-Núñez JJ; Monreal M;
    Thromb Res; 2020 Sep; 193():160-165. PubMed ID: 32623185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies.
    Wu O; Morris S; Larsen TB; Skjøth F; Evans A; Bowrin K; Wojciechowski P; Margas W; Huelsebeck M
    Cardiovasc Ther; 2022; 2022():2756682. PubMed ID: 35801133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
    Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
    Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight.
    Wysokinski WE; Froehling DA; Houghton DE; McBane RD; Vlazny DT; Bott-Kitslaar DM; Kuczmik W; Sutkowska K; Bator K; Hodge DO; Peterson LG; Casanegra AI
    Eur J Haematol; 2020 Oct; 105(4):484-494. PubMed ID: 32557773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.
    Hanigan S; Das J; Pogue K; Barnes GD; Dorsch MP
    J Thromb Thrombolysis; 2020 May; 49(4):636-643. PubMed ID: 31925665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
    PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
    Kimpton M; Carrier M
    Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
    Folkerts K; Broughton J; Sheikh U; Mckaig S
    J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
    [No Abstract]   [Full Text] [Related]  

  • 36. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility].
    Schastlivtsev IV; Lobastov KV
    Khirurgiia (Mosk); 2020; (7):68-75. PubMed ID: 32736466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
    N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
    Voigtlaender M; Langer F
    Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.